Today announced the top-range data from its double-blind.

Ceregene announces top-series data from CERE-12 Phase 2b clinical study for Parkinson’s disease Ceregene, Inc. Today announced the top-range data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 , a gene therapy product made to deliver the neurotrophic factor neurturin, for Parkinson's disease tadalafil . The trial didn’t demonstrate statistically significant efficacy on the principal endpoint . Nevertheless, among the ‘essential secondary endpoints’ , as defined and prespecified in the Statistical Evaluation Plan, did produce statistically significant advantage.